These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14724791)

  • 1. Molecular biology of the human immunodeficiency virus: current and future targets for intervention.
    Krogstad P
    Semin Pediatr Infect Dis; 2003 Oct; 14(4):258-68. PubMed ID: 14724791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antiretroviral agents: looking beyond protease and reverse transcriptase.
    Miller MD; Hazuda DJ
    Curr Opin Microbiol; 2001 Oct; 4(5):535-9. PubMed ID: 11587929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.
    Menéndez-Arias L
    Antiviral Res; 2013 Apr; 98(1):93-120. PubMed ID: 23403210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
    Sierra-Aragón S; Walter H
    Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
    Garbelli A; Riva V; Crespan E; Maga G
    Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches.
    Shet A; Markowitz M
    Curr Opin Investig Drugs; 2006 Aug; 7(8):709-20. PubMed ID: 16955682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors.
    Imamichi T
    Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structural biology of HIV-1: mechanistic and therapeutic insights.
    Engelman A; Cherepanov P
    Nat Rev Microbiol; 2012 Mar; 10(4):279-90. PubMed ID: 22421880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 11. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The HIV replication cycle. Established therapeutic targets and potential targets].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():3-10. PubMed ID: 19572419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stages of HIV replication and targets for therapeutic intervention.
    Tözsér J
    Curr Top Med Chem; 2003; 3(13):1447-57. PubMed ID: 14529520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
    Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
    J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy.
    Hauber I; Bevec D; Heukeshoven J; Krätzer F; Horn F; Choidas A; Harrer T; Hauber J
    J Clin Invest; 2005 Jan; 115(1):76-85. PubMed ID: 15630446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host factors and efficacy of antiretroviral treatment.
    Turriziani O; Antonelli G
    New Microbiol; 2004 Apr; 27(2 Suppl 1):63-9. PubMed ID: 15646066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.
    Gerber JG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S123-9. PubMed ID: 10860896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea to inhibit human immunodeficiency virus-1 replication.
    Romanelli F; Pomeroy C; Smith KM
    Pharmacotherapy; 1999 Feb; 19(2):196-204. PubMed ID: 10030769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candidate microbicides and their mechanisms of action.
    Herrera C; Shattock RJ
    Curr Top Microbiol Immunol; 2014; 383():1-25. PubMed ID: 23612992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.